Integrated Filing — IndAS



General information about company

Scrip Code 531349
NSE Symbol PANACEABIO
MSEI Symbol NOTLISTED
ISIN INE922B01023
Name of company Panacea Biotec Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 14-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 05-11-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 14-11-2026   16:00:00
End date and time of board meeting 14-11-2026   18:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 18,967.00 38,924.00
Other income 660.00 1,084.00
Total income 19,627.00 40,008.00
2 Expenses
(a) Cost of materials consumed 9,737.00 17,154.00
(b) Purchases of stock-in-trade 170.00 247.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (2,102.00) 575.00
(d) Employee benefit expense 4,621.00 9,037.00
(e) Finance costs 60.00 178.00
(f) Depreciation, depletion and amortisation expense 728.00 1,518.00
(f) Other Expenses
1 Other Expenses 4,991.00 9,794.00
Total other expenses 4,991.00 9,794.00
Total expenses 18,205.00 38,503.00
3 Total profit before exceptional items and tax 1,422.00 1,505.00
4 Exceptional items 277.00 551.00
5 Total profit before tax 1,699.00 2,056.00
6 Tax expense
7 Current tax 129.00 168.00
8 Deferred tax 379.00 477.00
9 Total tax expenses 508.00 645.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,191.00 1,411.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 1,191.00 1,411.00
17 Other comprehensive income net of taxes 38.00 76.00
18 Total Comprehensive Income for the period 1,229.00 1,487.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 1,161.00 1,391.00
Total profit or loss, attributable to non-controlling interests 30.00 20.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 1,199.00 1,467.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 30.00 20.00
21 Details of equity share capital
Paid-up equity share capital 613.00 613.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.9 2.27
Diluted earnings (loss) per share from continuing operations 1.9 2.27
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.9 2.27
Diluted earnings (loss) per share from continuing and discontinued operations 1.9 2.27
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes: 1. The financial results for the quarter and half-year ended September 30, 2026 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on November 14, 2026, and have been reviewed by the statutory auditor of the Company. 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (“Ind AS”) notified under the Companies (Indian Accounting Standards) Rule, 2015, as amended from time to time, specified under section 133 of the Companies Act, 2013. 3. The consolidated financial results of the Company have been prepared by consolidating the unaudited financial results of the Company and its material subsidiary Panacea Biotec Pharma Limited (“PBPL”) for the respective periods, with the unaudited (management reviewed and approved) financial results of its wholly owned subsidiaries (“WOS”) and the enterprises over which the Company exercises control (“Enterprises”) (the Company, these subsidiaries and the Enterprises hereinafter collectively referred to as “the Group”) for the respective periods: (i) WOS: Meyten Realtech Private Limited, Panacea Biotec (International) S.A. (“PBS”), Panacea Biotec Germany GmbH (WOS through PBS) and Panacea Biotec Inc. (WOS through PBPL); and (ii) Enterprises*: PanEra Biotec Private Limited and Adveta Power Private Limited. *considered as a subsidiary for the purpose of consolidation as per Ind AS 110 4. During the quarter and half-year ended September 30, 2026, the Company has earned profits (including other comprehensive income) of Rs.1,105 lakh and Rs.1,272 lakh respectively (as against losses of Rs.1,563 lakh and Rs.2,231 lakh during the quarter and half-year ended September 30, 2025 respectively). The Company incurred losses (including other comprehensive income) of Rs.2,874 lakh during the year ended March 31, 2026 (Rs.1,518 lakh for the year ended March 31, 2025). As on September 30, 2026, the retained earnings of the Company are negative to the extent of Rs. 20,510 lakh (September 30, 2025: (Rs.21,140 lakhs)). The aforesaid conditions indicate the existence of uncertainty that may create doubt about the Company's ability to continue as a going concern. However, the retained earnings of the Group are positive as on September 30, 2026. The surplus funds remaining with the Group out of the sales of pharmaceutical formulations brands in India and Nepal in March 2022 have helped in strengthening the working capital position, setting up new facilities for enhancement of capacities for manufacturing of vaccines drug substance, scaling up its nutrition and pharmaceutical formulations business and pursuing other business opportunities. The Company has already received higher long-term business orders for vaccines from key institutional customers. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial results on a going concern basis



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 53,775.00
Capital work-in-progress 10,844.00
Investment property 1,535.00
Goodwill 0.00
Other intangible assets 649.00
Intangible assets under development 4,747.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 7.00
Trade receivables, non-current 0.00
Loans, non-current 2.00
Other non-current financial assets
1 Other financial assets 1,023.00
Total of other non-current financial assets 1,023.00
Total non-current financial assets 1,032.00
Deferred tax assets (net) 0.00
Other non-current assets
1 Other non-current assets 112.00
2 Income Tax Assets (net) 2,078.00
Total of other non-current assets 2,190.00
Total non-current assets 74,772.00
2 Current assets
Inventories 20,400.00
Current financial asset
Current investments 853.00
Trade receivables, current 9,731.00
Cash and cash equivalents 5,953.00
Bank balance other than cash and cash equivalents 1,604.00
Loans, current 394.00
Other current financial assets
Total of other current financial assets 6,525.00
Total current financial assets 25,060.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 12,250.00
Total of other current assets 12,250.00
Total current assets 57,710.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 1,32,482.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 613.00
Other equity 84,414.00
Total equity attributable to owners of parent 85,027.00
Non controlling interest (616.00)
Total equity 84,411.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 2,450.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other financial liabilities 100.00
Total of other non-current financial liabilities 100.00
Total non-current financial liabilities 2,550.00
Provisions, non-current 3,573.00
Deferred tax liabilities (net) 2,818.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 73.00
Total of other non-current liabilities 73.00
Total non-current liabilities 9,014.00
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,879.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 18,850.00
Total Trade payable 20,729.00
Other current financial liabilities
1 other financial liabilities 2,153.00
Total of other current financial liabilities 2,153.00
Total current financial liabilities 22,882.00
Other current liabilities 12,023.00
1 Other current liabilities 12,023.00
Total of other current liabilities 12,023.00
Provisions, current 3,781.00
Current tax liabilities (Net) 371.00
Deferred government grants, Current 0.00
Total current liabilities 39,057.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 48,071.00
Total equity and liabilites 1,32,482.00
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) 5. During the half-year ended September 30, 2026, the Group has recognised exceptional income of Rs.551 lakh (half-year ended September 30, 2025: Rs.1,402 lakh) in the consolidated statement of profit and loss, which includes: (i) income of Rs.Nil (half-year ended September 30, 2025: Rs.858 Lakh, pursuant to the settlement agreement dated July 9, 2025 executed with Apotex Inc., USA (“Apotex”) to settle the ongoing dispute between Apotex and the Company & PBPL); and (ii) income of Rs.551 lakh (half-year ended September 30, 2025: Rs.544 lakh), out of the remaining deferred consideration of Rs.1,019 lakh as at March 31, 2026, from sale of domestic pharmaceutical brands of PBPL. The balance deferred consideration of Rs.468 lakh (September 30, 2025: Rs.1,567 lakh) would be recognised in subsequent quarters / years and is shown as Contract Liability in the consolidated financial statements of the Group. 6. The Company publishes standalone financial results along with the consolidated financial results. In accordance with Ind AS 108, ‘Operating Segments’, the management has disclosed the segment information in the consolidated financial results. Accordingly, the segment information is given in the consolidated financial results of the Group for the quarter and half year ended September 30, 2026. 7. The necessary certificate / report in respect of the above results in terms of requirements of Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015, has been placed before the Board of Directors. 8. Previous period amounts have been regrouped/ reclassified in compliance with Ind-AS to make them comparable with those of current period / year. 9. ‘0’ under “Rs. in Lakh” represents an amount less than Rs.50,000. Further, the figures shown in the tables may not exactly add up due to rounding off. 10. The above results are also available on the Company’s website https://www.panaceabiotec.com.



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Vaccines 12,422.00 25,889.00
2 Formulations 6,545.00 13,035.00
Total Segment Revenue 18,967.00 38,924.00
Less: Inter segment revenue 0.00 0.00
Revenue from operations 18,967.00 38,924.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Vaccines 1,685.00 2,432.00
2 Formulations 14.00 (376.00)
Total Profit before tax 1,699.00 2,056.00
i. Finance cost 0.00 0.00
ii. Other Unallocable Expenditure net off Unallocable income 0.00 0.00
Profit before tax 1,699.00 2,056.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Vaccines 92,927.00 92,927.00
2 Formulations 39,555.00 39,555.00
Total Segment Asset 1,32,482.00 1,32,482.00
Un-allocable Assets 0.00 0.00
Net Segment Asset 1,32,482.00 1,32,482.00
4 Segment Liabilities
Segment Liabilities
1 Vaccines 34,936.00 34,936.00
2 Formulations 13,135.00 13,135.00
Total Segment Liabilities 48,071.00 48,071.00
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 48,071.00 48,071.00
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss 50.00 101.00
Total Amount of items that will not be reclassified to profit and loss 50.00 101.00
2 Income tax relating to items that will not be reclassified to profit or loss 12.00 25.00
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss 0.00 0.00
Total Amount of items that will be reclassified to profit and loss 0.00 0.00
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 38.00 76.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 2,056.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 178.35
Adjustments for decrease (increase) in inventories (1,121.53)
Adjustments for decrease (increase) in trade receivables, current (2,385.69)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (1,237.73)
Adjustments for decrease (increase) in other non-current assets 5.22
Adjustments for other financial assets, non-current (4.45)
Adjustments for other financial assets, current 733.70
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 1,671.30
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 1,859.81
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,517.99
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (166.39)
Adjustments for provisions, non-current 121.75
Adjustments for other financial liabilities, current 337.00
Adjustments for other financial liabilities, non-current 54.24
Adjustments for unrealised foreign exchange losses gains 20.12
Adjustments for dividend income 0.00
Adjustments for interest income 179.14
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (50.07)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (619.48)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 735.00
Net cash flows from (used in) operations 2,791.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 453.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 2,338.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 13.44
Purchase of property, plant and equipment 1,377.86
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.45
Interest received 179.02
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (1,951.05)
Net cash flows from (used in) investing activities (3,136.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 1,102.00
Repayments of borrowings 0.00
Payments of lease liabilities 0.00
Dividends paid 95.00
Interest paid 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 1,007.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 209.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 13.00
Net increase (decrease) in cash and cash equivalents 222.00
Cash and cash equivalents cash flow statement at beginning of period 5,731.00
Cash and cash equivalents cash flow statement at end of period 5,953.00